Účtovná hodnota akcie spoločnosti Edesa Biotech

Aká je hodnota metriky Účtovná hodnota akcie spoločnosti Edesa Biotech?

Hodnota metriky Účtovná hodnota akcie spoločnosti Edesa Biotech, Inc. je 1.77

Aká je definícia metriky Účtovná hodnota akcie?

Účtovná hodnota akcie (Book/Share) sa rovná majetku spoločnosti mínus záväzky spoločnosti podelené počtom vydaných akcií.

The book value of a company is the value of its assets according to its balance sheet account balance. For assets, the value is based on the original cost of the asset less any depreciation, amortization or impairment costs made against the asset. Traditionally, a company's book value is its total assets minus intangible assets and liabilities. However, in practice, depending on the source of the calculation, book value may variably include goodwill, intangible assets, or both. The value inherent in its workforce, part of the intellectual capital of a company, is always ignored. The book value of a company may be also referred as with the term net asset value.

The book value per share is the the balance sheet equity value divided by the number of shares outstanding at the date of the balance sheet. Book value per share can be used to generate a measure of comprehensive earnings, when the opening and closing values are reconciled. The sale of shares/units by a business increases the total book value. Book value per share will increase if the additional shares are issued at a price higher than the pre-existing book value per share. The purchase of its own shares by a business will decrease total book value. Book value per share will decrease if more is paid for them than was received when originally issued. Dividends paid out will decrease book value per share value.

Účtovná hodnota akcie spoločností v sektore Health Care sektor na NASDAQ v porovnaní so spoločnosťou Edesa Biotech

Čomu sa venuje spoločnosť Edesa Biotech?

Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.

Firmy s metrikou účtovná hodnota akcie podobnou spoločnosti Edesa Biotech